Cargando…
Genetic validation of PfFKBP35 as an antimalarial drug target
Plasmodium falciparum accounts for the majority of over 600,000 malaria-associated deaths annually. Parasites resistant to nearly all antimalarials have emerged and the need for drugs with alternative modes of action is thus undoubted. The FK506-binding protein PfFKBP35 has gained attention as a pro...
Autores principales: | Thommen, Basil T, Dziekan, Jerzy M, Achcar, Fiona, Tjia, Seth, Passecker, Armin, Buczak, Katarzyna, Gumpp, Christin, Schmidt, Alexander, Rottmann, Matthias, Grüring, Christof, Marti, Matthias, Bozdech, Zbynek, Brancucci, Nicolas MB |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629825/ https://www.ncbi.nlm.nih.gov/pubmed/37934560 http://dx.doi.org/10.7554/eLife.86975 |
Ejemplares similares
-
Revisiting the Effect of Pharmaceuticals on Transmission Stage Formation in the Malaria Parasite Plasmodium falciparum
por: Thommen, Basil T., et al.
Publicado: (2022) -
New In Vitro Interaction-Parasite Reduction Ratio Assay for Early Derisk in Clinical Development of Antimalarial Combinations
por: Wicha, Sebastian G., et al.
Publicado: (2022) -
On a mission to block transmission
por: Ross, Amanda, et al.
Publicado: (2018) -
Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation Inhibitor
por: Rottmann, Matthias, et al.
Publicado: (2020) -
Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment
por: Radohery, Georges F. R., et al.
Publicado: (2022)